NASDAQ: ADXN
Addex Therapeutics Ltd Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their ADXN stock forecasts and price targets.

Forecast return on equity

Is ADXN forecast to generate an efficient return?

Company
N/A
Industry
75.98%
Market
342.02%

Forecast return on assets

Is ADXN forecast to generate an efficient return on assets?

Company
N/A
Industry
22.59%

ADXN earnings per share forecast

What is ADXN's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.07
Avg 2 year Forecast
-$0.04

ADXN revenue forecast

What is ADXN's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$765.0k+286.03%
Avg 2 year Forecast
$765.0k+286.03%
Avg 3 year Forecast
$0.0-100%
ADXN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ADXN revenue growth forecast

How is ADXN forecast to perform vs Biotechnology companies and vs the US market?

Company
62.52%
Industry
286.29%
Market
58.59%
ADXN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ADXN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ADXN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ADXN$7.77N/AN/A
REVB$1.04N/AN/A
GLMD$1.12N/AN/A
VIVS$2.32N/AN/A
CELZ$2.34N/AN/A

Addex Therapeutics Stock Forecast FAQ

What is ADXN's earnings growth forecast for 2025-2026?

(NASDAQ: ADXN) Addex Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 73.4%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 104.81%.

Addex Therapeutics's earnings in 2025 is -$7,621,243.On average, 3 Wall Street analysts forecast ADXN's earnings for 2025 to be -$7,020,312, with the lowest ADXN earnings forecast at -$6,745,006, and the highest ADXN earnings forecast at -$7,226,792.

In 2026, ADXN is forecast to generate -$4,011,607 in earnings, with the lowest earnings forecast at -$3,854,289 and the highest earnings forecast at -$4,129,595.

If you're new to stock investing, here's how to buy Addex Therapeutics stock.

What is ADXN's revenue growth forecast for 2025-2027?

(NASDAQ: ADXN) Addex Therapeutics's forecast annual revenue growth rate of 62.52% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 286.29%, and while it is forecast to beat the US market's average forecast revenue growth rate of 58.59%.

Addex Therapeutics's revenue in 2025 is $198,172.On average, 4 Wall Street analysts forecast ADXN's revenue for 2025 to be $75,217,631, with the lowest ADXN revenue forecast at $0, and the highest ADXN revenue forecast at $154,859,828. On average, 4 Wall Street analysts forecast ADXN's revenue for 2026 to be $75,217,631, with the lowest ADXN revenue forecast at $0, and the highest ADXN revenue forecast at $154,859,828.

In 2027, ADXN is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is ADXN's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: ADXN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 22.59%.

What is ADXN's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: ADXN) Addex Therapeutics's current Earnings Per Share (EPS) is -$0.06. On average, analysts forecast that ADXN's EPS will be -$0.07 for 2025, with the lowest EPS forecast at -$0.07, and the highest EPS forecast at -$0.07. In 2026, ADXN's EPS is forecast to hit -$0.04 (min: -$0.04, max: -$0.04).

What is ADXN's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: ADXN) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.